This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Sep 2026 quarter consolidated profit after tax Rs 205.13 lakh versus Rs 67.92 lakh a year earlier
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended 30 September 2026, revenue from operations was Rs 92.63 lakh against no prior figure reported, while profit after tax was Rs 205.13 lakh versus Rs 67.92 lakh a year earlier. The prior figures are standalone and not directly comparable because Greshma became a subsidiary on 1 August 2026. Consolidated half-year profit was Rs 547.24 lakh and operating cash flow was negative Rs 130.16 lakh.
Profit growth is positive, but the new consolidation makes comparisons uneven. Negative half-year operating cash flow is a concern.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.00 Cr | unchanged |
| Operating profit | −₹1.14 Cr | −₹0.74 Cr | loss widened |
| Profit after tax | ₹2.03 Cr | ₹0.68 Cr | +198.4% |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.